Publications by authors named "Alice Loo"

Claim this Profile
C
Correspondence on "Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase".
Wolfgang Jahnke, Johannes Paladini, Judith M Habazettl, Andrea Wiget, Alice Loo

Angew Chem Int Ed Engl· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Chen Liu, Hengyu Lu, Hongyun Wang, Alice Loo, Xiamei Zhang

Clin Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts.
Adam C Palmer, Deborah Plana, Hui Gao, Joshua M Korn, Guizhi Yang, Alice Loo

Cancer Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition.
Anne Fassl, Christopher Brain, Monther Abu-Remaileh, Iga Stukan, Deborah Butter, Alice Loo

Sci Adv· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Sunkyu Kim, Ralph Tiedt, Alice Loo, Thomas Horn, Scott Delach

Oncotarget· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-derived glioblastoma cultures as a tool for small-molecule drug discovery.
Ling F Ye, Eduard Reznik, Joshua M Korn, Fallon Lin, Guizhi Yang, Alice Loo

Oncotarget· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Sunkyu Kim, Ralph Tiedt, Alice Loo, Thomas Horn, Scott Delach

Oncotarget· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, Silvia Buonamici, Simona Cotesta, Alice Loo

J Med Chem· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.
E Robert McDonald, Antoine de Weck, Michael R Schlabach, Eric Billy, Konstantinos J Mavrakis, Alice T Loo

Cell· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.
Heather E Burks, Tinya Abrams, Christina A Kirby, Jason Baird, Alexander Fekete, Alice Loo

J Med Chem· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, Sandra W Cowan-Jacob, Alice Loo

Nature· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.
Hui Gao, Joshua M Korn, Stéphane Ferretti, John E Monahan, Youzhen Wang, Alice Loo

Nat Med· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.
Yi-Xiang Zhang, Ewa Sicinska, Jeffrey T Czaplinski, Stephen P Remillard, Samuel Moss, Alice Loo

Mol Cancer Ther· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting HSF1 sensitizes cancer cells to HSP90 inhibition.
Yaoyu Chen, Jinyun Chen, Alice Loo, Savina Jaeger, Linda Bagdasarian

Oncotarget· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-(N-Benzyl-N-phenylsulfonamido)alkyl amide derivatives as γ-secretase inhibitors.
Michael F Parker, Donna M Barten, Carl P Bergstrom, Joanne J Bronson, Jason A Corsa, Alice Loo

Bioorg Med Chem Lett· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.
Young Shin Cho, Hayley Angove, Christopher Brain, Christine Hiu-Tung Chen, Hong Cheng, Alice Loo

ACS Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling.
Alix Scholer-Dahirel, Michael R Schlabach, Alice Loo, Linda Bagdasarian, Ronald Meyer

Proc Natl Acad Sci U S A· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
Tara L Naylor, Huaping Tang, Boris A Ratsch, Andreas Enns, Alice Loo

Cancer Res· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells.
Zainab Jagani, Dmitri Wiederschain, Alice Loo, Dan He, Rebecca Mosher

Cancer Res· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The landscape of somatic copy-number alteration across human cancers.
Rameen Beroukhim, Craig H Mermel, Dale Porter, Guo Wei, Soumya Raychaudhuri, Alice Loo

Nature· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
Susan Wee, Zainab Jagani, Kay Xiaoqin Xiang, Alice Loo, Marion Dorsch

Cancer Res· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-vector inducible lentiviral RNAi system for oncology target validation.
Dmitri Wiederschain, Susan Wee, Lin Chen, Alice Loo, Guizhi Yang

Cell Cycle· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PTEN-deficient cancers depend on PIK3CB.
Susan Wee, Dmitri Wiederschain, Sauveur-Michel Maira, Alice Loo, Christine Miller

Proc Natl Acad Sci U S A· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amino-caprolactam derivatives as gamma-secretase inhibitors.
Michael F Parker, Joanne J Bronson, Donna M Barten, Jason A Corsa, Wengsheng Du, Alice Loo

Bioorg Med Chem Lett· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease.
C V C Prasad, Ming Zheng, Shikha Vig, Carl Bergstrom, David W Smith, Alice Loo

Bioorg Med Chem Lett· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis